Patent ID: 6642217
Filing Date: 2003-11-04
Classification: A61K,A61P,C07J

Abstract:
A therapeutic method of treating a mammal afflicted with a fungal infection comprising administering to the mammal an effective anti-fungal amount of a triterpene of formula (I): whereinR1 is hydrogen or hydroxy; R2 is a direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl, (C6-C10)aryl, or (C1-C6)alkyl; R3 is hydrogen, hydroxy, (C1-C6)alkyl, O&boxH;P(OH)2, O&boxH;P(OH)2OP(O)(OH)â€”, (C1-C5)alkanoyl, Si(R)3 wherein each R is H, phenyl or (C1-C6)alkyl, C(O)N(R)2, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C1-C4)alkoxy](C1-C4)alkyl, or a glycoside; R4 is hydrogen, hydroxy, (C1-C6)alkyl, O&boxH;P(OH)2, O&boxH;P(OH)2OP(O)(OH)â€”, (C1-C5)alkanoyl, Si(R)3 wherein each R is H, phenyl or (C1-C6)alkyl, C(O)N(R)2, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C1-C4)alkoxy](C1-C4)alkyl, or a glycoside; or R4 and R5 together are oxo; and R5 is direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl, (C6-C10)aryl, or (C1-C6)alkyl; or R4 and R5 together are oxo; wherein any alkyl can optionally be substituted with one or more halo, hydroxy, (C6-C10)aryl, nitro, cyano, (C1-C6)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo NR7R8, wherein R7 and R8 are each independently hydrogen, (C1-C6)alkyl or polyethyleneimine; or C(&boxH;O)OR9, wherein R9 is hydrogen, (C1-C6)alkyl, or polyethyleneimine; the bond between carbons 1 and 2 is a single bond or a double bond; wherein any alkyl is optionally interrupted on carbon with one or more oxy, thio, sulfinyl, sulfonyl, polyethyleneimine, or poly(ethylene glycol); wherein any alkyl is optionally partially unsaturated; wherein any aryl can optionally be substituted with one or more halo, hydroxy, nitro, cyano, (C1-C6)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo, NR7R8, wherein R7 and R8 are each independently hydrogen, (C1-C6)alkyl or polyethyleneimine; or C(&boxH;O)OR9, wherein R9 is hydrogen, (C1-C6)alkyl, or polyethyleneimine; or a pharmaceutically acceptable salt thereof, wherein the fungal infection is caused by a dermatophytic fungus, Candida albicans, or Candida guilliermondii.